Could a vaccine tame chronic hepatitis b?

NCT ID NCT04843852

Recruiting now Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study is testing whether HEPLISAV-B, a vaccine normally used to prevent hepatitis B, is safe for people who already have chronic hepatitis B. Ten adults on stable antiviral therapy will receive two vaccine shots and be monitored for side effects and immune responses over 14 months. The goal is to see if the vaccine can safely boost the body's fight against the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HEPLISAV-B (hepatitis B vaccine with an adjuvant to boost immune response)
What this could lead to: If it works, this could point toward a way to help the immune system better control chronic hepatitis B, potentially reducing the need for lifelong medication.
What could go wrong: This is a very small, early-stage safety trial with only 10 participants. It is not designed to prove the vaccine works for treatment, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B HEPATITIS B

Contacts and locations

Locations

Institute of Human Virology, University of Maryland School of Medicine
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.